C. GARRISON FATHMAN, MD
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California C33057
Category
Osteopathic Medicine
Type
Allergy & Immunology
Address
Address
2
300 Pasteur Dr, Palo Alto, CA 94305
177 Grove Dr, Menlo Park, CA 94028
177 Grove Dr, Menlo Park, CA 94028
Phone
(650) 851-5866
(650) 725-1958 (Fax)
(650) 725-1958 (Fax)
Organization information
See more information about C. GARRISON FATHMAN at bizstanding.comC Garrison Fathman MD
269 Campus Dr, Stanford, CA 94305
Categories:
Government Contractors, Physicians & Surgeons
Phone:
(650) 723-7887 (Phone)
Professional information
Anergy Associated Genes
US Patent:
6709840, Mar 23, 2004
Filed:
May 11, 2001
Appl. No.:
09/854300
Inventors:
Gregory Ford - Sunnyvale CA
Debra Bloom - Sun Prairie WI
C. Garrison Fathman - Stanford CA
Debra Bloom - Sun Prairie WI
C. Garrison Fathman - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C07H 2104
US Classification:
435 691, 4352523, 4353201, 536 235, 536 2431, 536 2433
Abstract:
Isolated nucleic acid compositions and sequences of anergy associated genes are provided, including the novel GRAIL gene. Expression of these genes is upregulated during the early stages of induction of anergy. The murine GRAIL sequence is shown to attenuate IL-2 transcription in T cells during response to antigenic stimulation. The identification of genes involved in the induction of anergy is useful in the evaluation of the pathophysiology or immunotherapy of cancer, autoimmune disease, and transplant rejection. Genetic sequences involved in anergy induction are useful markers in the evaluation of specific immunotherapies. Functional characterization of genes involved in anergy induction allows the elucidation of the mechanism(s) of T cell anergy, including the transcriptional blockade of IL-2, which may be manipulated to regulate T cell responses in human disease. The signaling pathways involving GRAIL are of significant interest in the identification of drugs that either block or upregulate the function(s) of GRAIL.
Transient Expression Of Immunomodulatory Polypeptides For The Prevention And Treatment Of Autoimmune Disease, Allergy And Transplant Rejection
US Patent:
8513208, Aug 20, 2013
Filed:
Feb 27, 2009
Appl. No.:
12/735932
Inventors:
Charles A. Nicolette - Durham NC, US
C. Garrison Fathman - Portola Valley CA, US
Remi Creusot - San Francisco CA, US
C. Garrison Fathman - Portola Valley CA, US
Remi Creusot - San Francisco CA, US
Assignee:
Argos Therapeutics, Inc. - Durham NC
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C07H 21/02, C12Q 1/68
US Classification:
514 44, 536 231, 435 61
Abstract:
A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-γ receptor antagonist, an IFN-α receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.
Method Of Conferring Immunotolerance To A Specific Antigen
US Patent:
4681760, Jul 21, 1987
Filed:
Apr 17, 1985
Appl. No.:
6/724063
Inventors:
C. Garrison Fathman - Menlo Park CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61K 3900, A61K 3935, A61K 39395
US Classification:
424 85
Abstract:
A method of selectively suppressing the immune system and conferring immunotolerance against a specific antigen by interferring with the L3T4 differentiation antigens on helper T cells is described. Simultaneous administration of a binding moiety specific for the L3T4-equivalent in the subject species and a specific antigen results in a diminished ability of the subject to respond immunologically to the antigen, whether or not the subject has been exposed previously to the antigen.
Method Of Conferring Immuno-Tolerance To A Specific Antigen
US Patent:
4904481, Feb 27, 1990
Filed:
Mar 20, 1987
Appl. No.:
7/028682
Inventors:
C. Garrison Fathman - Menlo Park CA
Assignee:
The Board of Trustess of Leland Stanford University - Stanford CA
International Classification:
A61K 3900, A61K 39395
US Classification:
424 858
Abstract:
A method of selectively suppressing the immune system and conferring immunotolerance against a specific antigen by interferring with the L3T4 differentiation antigens on helper T cells is described. Simultaneous administration of a binding moiety specific for the L3T4-equivalent in the subject species and a specific antigen or administration of the antigen subsequent to the binding moiety for L3T4-equivalent within the time required for T-cell recovery results in a diminished ability of the subject to respond immunologically to the antigen, whether or not the subject has been exposed previously to the antigen.
Polypeptide Complex That Regulates Cell Cycle And Anergy
US Patent:
7964369, Jun 21, 2011
Filed:
Nov 9, 2004
Appl. No.:
10/579049
Inventors:
C. Garrison Fathman - Stanford CA, US
Luis Soares - Stanford CA, US
Luis Soares - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
G01N 33/53, C12Q 1/00, C12P 19/34
US Classification:
435 79, 435 4, 435 9152, 977886, 424 945
Abstract:
An active ubiquitin E3 ligase, GRAIL, is crucial in the induction of anergy in cells of the immune system, and in the regulation of cellular proliferation. GRAIL is shown to associate with, and be regulated by Otubain isoforms, including OTUBAIN-1 (DOG, the Destabilizer of GRAIL) and an alternative reading frame splice variant of OTUBAIN-1 (SOG, the Stabilizer of GRAIL). These proteins play opposing roles in the regulation of GRAIL auto-ubiquitination and consequently on its ability to induce anergy and regulate cellular proliferation. DOG serves as an adaptor protein, recruiting the DUB USP8. One major substrate for USP8 is the Ras exchange factor Ras-GRF1, and this protein can be found in a complex with USP8 and GRAIL, which complex is ubiquitinated by GRAIL.
Compositions And Methods For Treating Diseases
US Patent:
8629115, Jan 14, 2014
Filed:
Oct 20, 2010
Appl. No.:
12/925357
Inventors:
Jonathan B. Rothbard - Woodside CA, US
Paul L. McGrane - Mountain View CA, US
Edgar G. Engleman - Atherton CA, US
C. Garrison Fathman - Portola Valley CA, US
Erik Kreider - Boulder CO, US
Paul L. McGrane - Mountain View CA, US
Edgar G. Engleman - Atherton CA, US
C. Garrison Fathman - Portola Valley CA, US
Erik Kreider - Boulder CO, US
Assignee:
Lumen Therapeutics, LLC - Menlo Park CA
International Classification:
A61K 38/08, A61K 38/16, A61K 38/18
US Classification:
514 217, 514 212, 514 81, 530328, 530324
Abstract:
This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
Compositions And Methods For Treating Diseases
US Patent:
7820626, Oct 26, 2010
Filed:
Oct 24, 2008
Appl. No.:
12/258265
Inventors:
Jonathan B. Rothbard - Woodside CA, US
Paul L. McGrane - Mountain View CA, US
Edgar G. Engleman - Atherton CA, US
C. Garrison Fathman - Portola Valley CA, US
Erik Kreider - Boulder CO, US
Paul L. McGrane - Mountain View CA, US
Edgar G. Engleman - Atherton CA, US
C. Garrison Fathman - Portola Valley CA, US
Erik Kreider - Boulder CO, US
Assignee:
Lumen Therapeutics, LLC - Menlo Park CA
International Classification:
A61K 38/03, C12P 13/10
US Classification:
514 217, 514 11, 435114, 530328
Abstract:
This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
Compositions And Methods For Treating Diseases
US Patent:
2005019, Sep 1, 2005
Filed:
Mar 1, 2005
Appl. No.:
11/070528
Inventors:
Jonathan Rothbard - Woodside CA, US
Paul McGrane - Mountain View CA, US
Edgar Engleman - Atherton CA, US
C. Fathman - Portola Valley CA, US
Erik Kreider - Boulder CO, US
Paul McGrane - Mountain View CA, US
Edgar Engleman - Atherton CA, US
C. Fathman - Portola Valley CA, US
Erik Kreider - Boulder CO, US
International Classification:
A61K038/00, A61K038/08, A61K031/5377, A61K031/4178, A61K031/137
US Classification:
514002000, 514017000, 514235500, 514397000, 514649000, 514509000
Abstract:
This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
Compositions And Methods For Treating Diseases
US Patent:
7557087, Jul 7, 2009
Filed:
Apr 18, 2007
Appl. No.:
11/736689
Inventors:
Jonathan B. Rothbard - Woodside CA, US
Paul L. McGrane - Mountain View CA, US
Edgar G. Engleman - Atherton CA, US
C. Garrison Fathman - Portola Valley CA, US
Erik Kreider - Boulder CO, US
Paul L. McGrane - Mountain View CA, US
Edgar G. Engleman - Atherton CA, US
C. Garrison Fathman - Portola Valley CA, US
Erik Kreider - Boulder CO, US
Assignee:
Lumen Therapeutics, LLC - Mountain View CA
International Classification:
A61K 38/08
US Classification:
514 16, 514 15, 514 14, 514 13, 514 12, 435114, 530329, 530324, 530325
Abstract:
This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
Anergy Genes
US Patent:
5747299, May 5, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/486955
Inventors:
Debra Bloom - Mountain View CA
C. Garrison Fathman - Portola Valley CA
Sarah Slaymaker - Stanford CA
C. Garrison Fathman - Portola Valley CA
Sarah Slaymaker - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
C12P 1934, C12Q 168, G01N 3300, C07H 2102
US Classification:
435 912
Abstract:
Methods and compositions are provided for identifying genes associated with induction of anergy in T-cells and the use of the nucleic acids or proteins as diagnostics for monitoring induction of tolerance for the presence of tolerized T-cells in a physiological sample, or elucidating the pathway to anergy or activation in T-cells. A cysteine string protein is found to indicate quiescent T-cells and is lost with anergic T-cells.